ZA932613B - Methanediphosphonic acid formulations with ion exchangers - Google Patents

Methanediphosphonic acid formulations with ion exchangers

Info

Publication number
ZA932613B
ZA932613B ZA932613A ZA932613A ZA932613B ZA 932613 B ZA932613 B ZA 932613B ZA 932613 A ZA932613 A ZA 932613A ZA 932613 A ZA932613 A ZA 932613A ZA 932613 B ZA932613 B ZA 932613B
Authority
ZA
South Africa
Prior art keywords
ion exchangers
disodium
acid formulations
administration form
methanediphosphonic acid
Prior art date
Application number
ZA932613A
Other languages
English (en)
Inventor
Satish Chandra Khanna
Jonathan Green
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA932613B publication Critical patent/ZA932613B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
ZA932613A 1992-04-15 1993-04-14 Methanediphosphonic acid formulations with ion exchangers ZA932613B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH124792 1992-04-15

Publications (1)

Publication Number Publication Date
ZA932613B true ZA932613B (en) 1993-10-26

Family

ID=4205927

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932613A ZA932613B (en) 1992-04-15 1993-04-14 Methanediphosphonic acid formulations with ion exchangers

Country Status (20)

Country Link
US (1) US5344825A (ko)
EP (1) EP0566535B1 (ko)
JP (1) JP3970941B2 (ko)
KR (1) KR100307786B1 (ko)
AT (1) ATE183096T1 (ko)
AU (1) AU665814B2 (ko)
CA (1) CA2093946C (ko)
DE (1) DE59309727D1 (ko)
DK (1) DK0566535T3 (ko)
ES (1) ES2137241T3 (ko)
FI (1) FI110920B (ko)
GR (1) GR3031645T3 (ko)
HU (1) HU219022B (ko)
IL (1) IL105382A (ko)
MX (1) MX9302151A (ko)
NO (1) NO306978B1 (ko)
NZ (1) NZ247398A (ko)
PH (1) PH30733A (ko)
TW (1) TW237386B (ko)
ZA (1) ZA932613B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) * 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
PL337813A1 (en) * 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
DE60111574T2 (de) * 2001-01-23 2006-05-11 Gador S.A. Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
MXPA04006027A (es) * 2001-12-21 2004-09-27 Procter & Gamble Metodo para el tratamiento de trastornos de los huesos.
JP2005522526A (ja) 2002-05-10 2005-07-28 エフ．ホフマン−ラ　ロシュ　アーゲー 骨粗鬆症の治療および予防用のビスホスホン酸
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
EP1790347B1 (en) * 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP4896480B2 (ja) * 2004-10-01 2012-03-14 第一三共ヘルスケア株式会社 陰イオン交換樹脂の粒子状組成物
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
CA3077421A1 (en) * 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System Inhalable composition of clofazimine and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
JPS57177012A (en) * 1981-04-23 1982-10-30 Sumitomo Chem Co Ltd Preparation of chelate resin
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
ATE61371T1 (de) * 1986-11-21 1991-03-15 Ciba Geigy Ag Neue substituiertaminomethandiphosphonsaeuren.
US5057505A (en) * 1986-11-21 1991-10-15 Ciba-Geigy Corporation Substituted aminomethanediphosphonic acids and use in medicaments
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate

Also Published As

Publication number Publication date
FI110920B (fi) 2003-04-30
GR3031645T3 (en) 2000-02-29
NZ247398A (en) 1995-07-26
AU3696193A (en) 1993-10-21
JP3970941B2 (ja) 2007-09-05
HU9301088D0 (en) 1993-06-28
EP0566535A1 (de) 1993-10-20
HUT63766A (en) 1993-10-28
IL105382A (en) 1998-06-15
KR940005268A (ko) 1994-03-21
FI931633A (fi) 1993-10-16
FI931633A0 (fi) 1993-04-08
CA2093946A1 (en) 1993-10-16
EP0566535B1 (de) 1999-08-11
NO931367L (no) 1993-10-18
DK0566535T3 (da) 2000-03-06
CA2093946C (en) 2005-07-05
PH30733A (en) 1997-10-17
DE59309727D1 (de) 1999-09-16
AU665814B2 (en) 1996-01-18
KR100307786B1 (ko) 2001-11-30
NO306978B1 (no) 2000-01-24
ATE183096T1 (de) 1999-08-15
IL105382A0 (en) 1993-08-18
TW237386B (ko) 1995-01-01
US5344825A (en) 1994-09-06
HU219022B (hu) 2001-04-28
ES2137241T3 (es) 1999-12-16
MX9302151A (es) 1993-10-01
JPH069408A (ja) 1994-01-18
NO931367D0 (no) 1993-04-14

Similar Documents

Publication Publication Date Title
PH30733A (en) Methanediphosphonic acid formulations with ion exchangers.
ZA892557B (en) Pharmaceutical composition for oral administration,based on a diphosphonic acid derivative
EP0202819A3 (en) A delivery system for an active ingredient and a process for preparation thereof
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
IL105403A0 (en) Pharmaceutical preparation and process for its manufacture
IL86697A (en) Ion exchange resins loaded with quinolonecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3374686D1 (en) 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ZA905861B (en) Pharmaceutical composition for oral administration containing nac
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
ZA881681B (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
AU3232684A (en) S-adenosyl-l-methionine salts preparation
CA2311024A1 (en) Pharmaceutical composition for oral administration of chelating agents
PH18051A (en) 3,4-bis-substituted 1,2,5-oxdiazole 2-oxides,a process for their preparation,and pharmaceutical formulations containing them
AU1039097A (en) A solution for oral administration containing ici 182,780
EP0419890A3 (en) Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
HK1001822A1 (en) Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride
AUPM814994A0 (en) Codeine-containing formulations
AU1283188A (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable nondigestible anion exchange resin
Ellsworth et al. Tolerance to two different forms of oral erythromycin.
Lessard Short Pieces for Piano (For Aaron)
EP0356254A3 (en) Pharmaceutical formulations
IT1255380B (it) Nitrobenzoilalanine,procedimento per la loro preparazione,loro uso come agenti terapeutici e composizioni farmaceutiche che le contengono